Risk factors for colorectal neoplasia in inflammatory bowel disease: a nested case-control study from Copenhagen county, Denmark and Olmsted county, Minnesota
Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Standard
Risk factors for colorectal neoplasia in inflammatory bowel disease : a nested case-control study from Copenhagen county, Denmark and Olmsted county, Minnesota. / Jess, Tine; Loftus, Edward V; Velayos, Fernando S; Winther, Karen V; Tremaine, William J; Zinsmeister, Alan R; Scott Harmsen, W; Langholz, Ebbe; Binder, Vibeke; Munkholm, Pia; Sandborn, William J.
I: The American Journal of Gastroenterology, Bind 102, Nr. 4, 04.2007, s. 829-36.Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Risk factors for colorectal neoplasia in inflammatory bowel disease
T2 - a nested case-control study from Copenhagen county, Denmark and Olmsted county, Minnesota
AU - Jess, Tine
AU - Loftus, Edward V
AU - Velayos, Fernando S
AU - Winther, Karen V
AU - Tremaine, William J
AU - Zinsmeister, Alan R
AU - Scott Harmsen, W
AU - Langholz, Ebbe
AU - Binder, Vibeke
AU - Munkholm, Pia
AU - Sandborn, William J
PY - 2007/4
Y1 - 2007/4
N2 - OBJECTIVES: Population-based data on risk factors and protective factors for colorectal dysplasia and cancer in patients with inflammatory bowel disease (IBD) are sparse. We conducted a nested case-control study of such factors in two well-described IBD cohorts from Copenhagen County, Denmark and Olmsted County, Minnesota.METHODS: Forty-three neoplasia cases were matched on six criteria to 1-3 controls (N = 102). Medical records were scrutinized for demographic and clinical data. For each variable, the odds of neoplasia were estimated using conditional logistic regression.RESULTS: Primary sclerosing cholangitis (PSC) (odds ratio [OR] 6.9, 95% confidence interval [CI] 1.2-40), percentage of disease course with clinically active disease (OR [per 5% increase] 1.2, 95% CI 0.996-1.4), and >or=1 yr of continuous symptoms (OR 3.2, 95% CI 1.2-8.6) were associated with neoplasia, whereas a borderline association with median number of small-bowel x-rays (OR 1.3, 95% CI 0.96-1.6) was observed. We did not observe a protective effect of frequency of physician visits (OR 1.4, 95% CI 0.96-2.0), number of colonoscopies (OR 1.4, 95% CI 1.0-2.1), cumulative dose of sulfasalazine (OR [per 1,000 g] 1.1, 95% CI 1.0-1.3) and mesalamine (OR [per 1,000 g] 1.3, 95% CI 0.9-1.9), or partial intestinal resections (OR 1.5, 95% CI 0.3-7.1).CONCLUSIONS: Subgroups of IBD patients-those with PSC, severe long-standing disease, and exposure to x-ray-were at greater risk of colorectal neoplasia. The protective effect of close follow-up, colonoscopy, and treatment with 5-aminosalicylates was questionable.
AB - OBJECTIVES: Population-based data on risk factors and protective factors for colorectal dysplasia and cancer in patients with inflammatory bowel disease (IBD) are sparse. We conducted a nested case-control study of such factors in two well-described IBD cohorts from Copenhagen County, Denmark and Olmsted County, Minnesota.METHODS: Forty-three neoplasia cases were matched on six criteria to 1-3 controls (N = 102). Medical records were scrutinized for demographic and clinical data. For each variable, the odds of neoplasia were estimated using conditional logistic regression.RESULTS: Primary sclerosing cholangitis (PSC) (odds ratio [OR] 6.9, 95% confidence interval [CI] 1.2-40), percentage of disease course with clinically active disease (OR [per 5% increase] 1.2, 95% CI 0.996-1.4), and >or=1 yr of continuous symptoms (OR 3.2, 95% CI 1.2-8.6) were associated with neoplasia, whereas a borderline association with median number of small-bowel x-rays (OR 1.3, 95% CI 0.96-1.6) was observed. We did not observe a protective effect of frequency of physician visits (OR 1.4, 95% CI 0.96-2.0), number of colonoscopies (OR 1.4, 95% CI 1.0-2.1), cumulative dose of sulfasalazine (OR [per 1,000 g] 1.1, 95% CI 1.0-1.3) and mesalamine (OR [per 1,000 g] 1.3, 95% CI 0.9-1.9), or partial intestinal resections (OR 1.5, 95% CI 0.3-7.1).CONCLUSIONS: Subgroups of IBD patients-those with PSC, severe long-standing disease, and exposure to x-ray-were at greater risk of colorectal neoplasia. The protective effect of close follow-up, colonoscopy, and treatment with 5-aminosalicylates was questionable.
KW - Adult
KW - Case-Control Studies
KW - Colonoscopy
KW - Colorectal Neoplasms/epidemiology
KW - Denmark/epidemiology
KW - Female
KW - Gastrointestinal Agents/therapeutic use
KW - Humans
KW - Inflammatory Bowel Diseases/complications
KW - Logistic Models
KW - Male
KW - Mesalamine/therapeutic use
KW - Minnesota/epidemiology
KW - Population Surveillance
KW - Precancerous Conditions/epidemiology
KW - Prognosis
KW - Risk Factors
KW - Sulfasalazine/therapeutic use
U2 - 10.1111/j.1572-0241.2007.01070.x
DO - 10.1111/j.1572-0241.2007.01070.x
M3 - Journal article
C2 - 17222314
VL - 102
SP - 829
EP - 836
JO - The American Journal of Gastroenterology
JF - The American Journal of Gastroenterology
SN - 0002-9270
IS - 4
ER -
ID: 219529680